The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

The HIF prolyl hydroxylase inhibitor shows efficacy in the treatment of anemia with chronic kidney disease, but in non-dialysis patients increased cardiovascular risks are observed.

Peter L. Salgo, MD: Hello, everybody. We’re going to be discussing the link between chronic kidney disease [CKD] and anemia. We’re going to take a look at some of the commonly held beliefs ...

During the last 3 decades, only one class of drugs – erythropoiesis-stimulating agents – has been available to treat anemia in patients with end-stage kidney disease. That has now changed ...

Underuse of erythropoiesis-stimulating agents (ESA) and ESA hyporesponsiveness are 2 important reasons for red blood cell transfusion, according to a recent review.

Are vitamin B12 supplements helpful for a person living with chronic kidney disease (CKD)? Read on to learn more, such as how they may help with complications of CKD.

Akebia is much undervalued compared to the closest competitor Fibrogen despite similar acting drugs which have shown efficacy in treating anemia in chronic kidney disease.

Roxadustat is now under FDA review for treating anemia of chronic kidney disease, in both non-dialysis-dependent and dialysis-dependent patients, with a PDUFA date of Dec. 20, 2020. In this ...

Healio spoke with Jay B. Wish, MD, about treatment approaches in patients with CKD and anemia.

Akebia Therapeutics, Inc. AKBA announced that the FDA has approved its Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD). The eligible patient population ...

Chronic kidney disease and anemia—both individually and together—spell bad news (in the form of increased mortality risk) for patients with heart failure, say the results of a new study of ...

Jesduvroq (daprodustat) is approved to treat anemia due to CKD in adults who have been receiving dialysis for at least 4 months.